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87In the TAILORIX trial, no benefit could be shown by infliximab dose escalation based on
pharmacokinetic (infliximab serum concentrations) and pharmacodynamic (biomarkers and
symptoms) monitoring compared with dose escalation based on symptoms alone in patients
with Crohn’s disease (CD). We investigated whether integration of pharmacokinetic and
pharmacodynamic monitoring can be used to evaluate responses to infliximab induction and







95We performed a post hoc analysis of patients with CD included in a trial to test the effects of
infliximab dose escalation, based on biomarkers and serum concentrations of infliximab, on
symptoms (the TAILORIX trial; n [ 122). We analyzed data from this study to determine
whether concentrations of biomarkers and serum concentrations of infliximab were associ-
ated with endoscopic outcomes (n [ 116). The primary end points were endoscopic response
(CD endoscopic index of severity decrease ‡50% from baseline), endoscopic remission (CD












107Infliximab trough concentrations greater than 23.1 mg/L at week 2 and greater than 10.0
mg/L at week 6 were associated with endoscopic remission at week 12 (positive predictive
values, 72% and 76%; negative predictive values, 65% and 59%, respectively). During
maintenance therapy, we found evidence for an exposure–response relationship only after
dose escalation; trough concentrations greater than 10.6 mg/L were associated with the
absence of ulcers at week 54 (positive predictive value, 49%; negative predictive value,
92%). Low fecal concentrations of calprotectin during therapy were associated with
endoscopic response and remission (P < .05). Dose escalations increased trough concen-
trations of infliximab; persistent increase in fecal concentration of calprotectin, despite
dose escalation, was associated with a lack of endoscopic response and remission. A
significantly higher proportion of patients with antibodies to infliximab, identified by aer: ATI, antibodies to infliximab; AUROC,
ing characteristic curve; CD, Crohn’s dis-
tivity index; CRP, C-reactive protein; fCal,
artile range; MH, mucosal healing; NPV,
pharmacodynamic; PK, pharmacokinetic;
; TAILORIX, _______________; TC, trough
c drug monitoring.
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182In a post hoc analysis of data from a trial to test the effects of infliximab dose escalation on
symptoms, we found that during maintenance therapy, the combination of fecal concentration
of calprotectin and trough concentration of infliximab can guide dose adjustment and increase
the chances for endoscopic response and remission. ClinicalTrialsRegister.eu EudraCT no:
















































232Mucosal healing (MH) is an important end pointfor clinical trials in Crohn’s disease (CD).
Recently, international guidelines also adopted this
concept into clinical practice, based on published evi-
dence that MH is associated with a reduction in hospi-
talizations and surgery.1 Treatment with infliximab is
effective for inducing and maintaining MH in patients
with luminal CD.2,3 In the pivotal SONIC trial, 38% of
patients showed disappearance of ulcerations by week
26 on infliximab therapy.4
Several retrospective cohort studies have shown an
association between infliximab serum concentrations
and clinical and endoscopic outcomes.5,6 Based on these
observations, the concept of therapeutic drug monitoring
(TDM) was introduced. TDM traditionally refers to dose
adjustment based on drug serum concentrations and
antidrug antibodies (pharmacokinetic [PK] monitoring).7
Although recent recommendations have suggested an
infliximab serum concentration at a trough of 5.0 mg/L
to be “therapeutic” during maintenance therapy, evi-
dence to support this recommendation was based mainly
on observational data.8 As such, TDM is not yet widely
used across the globe. To date, no solid therapeutic
thresholds have been established for MH.9
On top of PK monitoring, there is growing interest
in pharmacodynamic (PD) monitoring. PD monitoring
implies dose optimization guided by the effects of the
drug on disease manifestations such as changes in
biomarkers. One prospective trial evaluated adalimu-
mab dose optimization based on PD monitoring.10 In
this trial, it was shown that MH rates were higher
when dosing was based on symptoms and biomarker
monitoring (C-reactive protein [CRP] and fecal cal-
protectin [fCal]) instead of monitoring symptoms
alone.
In the TAILORIX trial, infliximab dose escalation was
based on a combination of PK (infliximab serum con-
centrations) and PD (symptoms and biomarkers) moni-
toring and compared with dose escalation based on
symptoms alone.11 No benefit could be shown for dose
escalation based on biomarkers and infliximab serum
concentrations as compared with symptoms. In the cur-
rent post hoc PK–PD analysis of TAILORIX, we examined
the roles of PK and PD monitoring during infliximab in-
duction and maintenance therapy for targeting endo-
scopic outcomes.LA 5.6.0 DTD  YJCGH56531_proof  1Methods
The TAILORIX Trial
TAILORIX was a multicenter, randomized, double-
blind, controlled trial that was designed to determine
the value of PK and PD monitoring during combined
infliximab–immunomodulator maintenance therapy,
with the goal to improve clinical and endoscopic remis-
sion rates in patients with CD.11 Briefly, 122 biologically
naive patients with active luminal CD (active ulceration
at endoscopy, CD activity index [CDAI] >220, fCal >250
mg/kg, and/or CRP >5 mg/L) started standard inflix-
imab induction therapy (5 mg/kg at weeks 0, 2, and 6) in
combination with an immunomodulator. From week 14
onward, patients were treated following 1 of 3 moni-
toring algorithms to which the patients were assigned
randomly. Two algorithms combined PK and PD moni-
toring (active arms; based on infliximab serum concen-
trations at trough in combination with CDAI, fCal, and/or
CRP), although 1 algorithm used PD monitoring only
(control arm; based on CDAI). Based on these algorithms,
the infliximab dose was increased by 2.5 mg/kg (active
arm 1) or 5 mg/kg (active arm 2 and control arm).
CRP, fCal, infliximab, and antibodies to infliximab (ATI)
were quantified at all patient visits (weeks 0, 2, 6, 12, 14,
and every 4 weeks thereafter until week 54).12 Albumin,
hemoglobin, hematocrit, lymphocyte count, platelet count,
mean platelet volume, and white blood cell count were
assessed at the standard infliximab infusion time points
only. Ileocolonoscopies were performed at weeks 0, 12,
and 54, videorecorded, and scored by endoscopists who
were blinded to patient identification and clinical data.
The CD endoscopic index of severity and the absence and/
or presence of ulceration were assessed. Endoscopic
outcomes were endoscopic response (CD endoscopic in-
dex of severity decrease of at least 50% from baseline),
endoscopic remission (CD endoscopic index of severity
<3), and absence of ulceration at weeks 12 and 54.Post Hoc Pharmacokinetic–Pharmacodynamic
Analysis of TAILORIX
We evaluated the role of PK and PD monitoring for
targeting endoscopic outcomes after infliximab induction6 January 2020  4:57 pm  ce DVC
Q18
Q19
What You Need to Know
Background
We investigated whether integration of pharmaco-
kinetic and pharmacodynamic monitoring can be
used to evaluate responses to infliximab induction
and maintenance therapy, based on findings from
endoscopy.
Findings
In a post hoc analysis of data from a trial to test the
effects of infliximab dose escalation on symptoms,
we found that during maintenance therapy, the
combination of fecal concentration of calprotectin
and trough concentration of infliximab can guide
dose adjustment and increase the chances for
endoscopic response and remission.
Implications for patient care
Fecal concentrations of calprotectin and trough
concentrations of infliximab should be monitored
during maintenance therapy of patients with Crohn’s
disease to determine chances of endoscopic
response.




















































































































348and maintenance therapy. First, we evaluated the pre-
dictive value of infliximab and biomarker concentrations
for endoscopic outcomes at weeks 12 and 54. Then, we
investigated whether biomarkers and other factors
influenced the infliximab PK. Finally, we examined the
effects of dose escalations.
These post hoc analyses were not prespecified per
TAILORIX protocol. Only patients with informative PK
data (at least 1 sample with detectable infliximab) were
included. Available case analysis was implemented to
address missing data.
Statistical Analyses
Descriptive statistics were stated as percentages for
discrete variables and as means  SD or median (inter-
quartile range [IQR]) for continuous variables. Concen-
trations that were lower than the limit of quantification
were replaced by the limit of quantification for statistical
analyses. The Fisher exact test or the Pearson chi-square
test was used for the analysis of discrete variables. A
paired 2-tailed Student t test or the Wilcoxon signed-
rank test was used for analysis of paired measure-
ments. Unpaired data were analyzed with the unpaired
Student t test or the Wilcoxon rank-sum test. Diagnostic
performance was assessed with receiver operating
characteristic analysis. Therapeutic threshold values
were selected using the Youden J statistic. Binary logistic
regression was conducted to identify independent pre-
dictors of the endoscopic outcomes of infliximab therapy.
Collinearity between signifcant predictors was defned as
a variance inflation factor greater than 5. A 2-sided P
value of .050 or less denoted statistical signifcance. Sta-
tistical analyses were performed using R (version 3.4.3;
R Core Team, Vienna, Austria).
All authors had access to the study data and reviewed
and approved the final manuscript.
Results
Study Population
Among the 122 patients enrolled in the TAILORIX
trial, 6 did not have informative PK data. Therefore, the
current post hoc analysis included 116 of 122 (95%)
patients (Table 1).
Induction Therapy
Pharmacokinetic monitoring. Endoscopic response,
endoscopic remission, and absence of ulceration were
achieved at week 12 in 82 of 106 (77%), 54 of 106
(51%), and 38 of 102 (37%) patients with available
endoscopic data. Infliximab trough concentrations (TC)
at weeks 2, 6, and 12 were significantly higher in patients
achieving these endoscopic outcomes at week 12,
although there was considerable variability (Figure 1). AFLA 5.6.0 DTD  YJCGH56531_proof  1TC greater than 23.1 mg/L at week 2 predicted endo-
scopic remission at week 12 (positive predictive value
[PPV], 72%; negative predictive value [NPV], 65%; me-
dian area under the receiver operating characteristic
curve [AUROC], 0.67; 95% CI, 0.57–0.78) (Figure 2A,
Supplementary Table 1). A TC greater than 10.0 mg/L at
week 6 predicted endoscopic remission at week 12 (PPV,
76%; NPV, 59%; AUROC, 0.64; 95% CI, 0.54–0.75)
(Figure 2B, Supplementary Table 1). Furthermore, the
proportion of patients achieving the endoscopic out-
comes increased with higher infliximab TC quartiles
(Supplementary Figure 1).
Pharmacodynamic monitoring. At baseline, CRP was
the only biomarker correlating with endoscopic remis-
sion at week 12, with a median baseline CRP of 17.0 mg/
L (IQR, 7.0–32.0 mg/L) in patients who achieved endo-
scopic remission, and 26.0 mg/L (IQR, 11.0–44.0 mg/L)
in those without endoscopic remission (P ¼ .025). Levels
of albumin, fCal, hemoglobin, hematocrit, white blood cell
count, lymphocyte count, platelet count, and mean
platelet volume did not correlate with endoscopic out-
comes. From the multivariable binary logistic regression
model, a lower CRP was the only baseline predictor for
endoscopic remission (log odds, -0.028  0.013; P ¼
.029) (Supplementary Table 2).
After the first infliximab dose, CRP decreased rapidly
and only fCal, platelet count, and lymphocyte count were
able to univariately predict which patients achieved the
endoscopic end points (Supplementary Figure 2). From
the multivariable models, higher fCal and lower platelet
count were retained as predictors of failure to achieve
the endoscopic outcomes (Supplementary Table 2).6 January 2020  4:57 pm  ce DVC
Q20




Sex, female, n (%) 68 (59)
Age, median, y (IQR) 30 (22–45)
Body weight, median, kg (IQR) 65 (57–75)
Disease duration, median, mo (IQR) 7 (1–78)
Serology concentrations at baseline
C-reactive protein, median, mg/L (IQR) 20.0 (9.0–36.5)
Fecal calprotectin, median, mg/kg (IQR) 1462.5 (725.8–1800.0)
Albumin, median, g/L (IQR) 39.0 (34.0–42.0)
Hemoglobin, median, g/dL (IQR) 12.7 (11.8–13.8)
Hematocrit, median, % (IQR) 39 (36–41)
Mean platelet volume, median,
fL (IQR)
9.4 (8.8–10.0)
Platelet count, median/mm3Q22 (IQR) 368,000 (287,500–455,500)
Lymphocyte count, median/mm3 (IQR) 1700 (1200–2200)
White blood cell count, median/mm3 (IQR) 8480 (7100–10,645)
Endoscopy at baseline
Crohn’s disease endoscopic index of severity, median (IQR) 7 (10–15)
Disease location, ileal:colonic:ileocolonic, n (%) 26:19:71 (22:16:61)
Disease behavior, nonstricturing nonpenetrating:stricturing:penetrating, n (%) 85:17:14 (73:15:12)
Infliximab dosages and ATIs during the study
Patients with ATIs, n (%) 21 (18)
Samples available, n 1329
Samples with undetectable infliximab, n (%) 32 (2.4)
Samples with ATIs, n (%) 84 (6.3)
Samples with undetectable infliximab and ATIs, n (%) 26 (2.0)
ATI, antibody to infliximab; IQR, interquartile range; n, number of patients.





















































































































Pharmacokinetic monitoring. Endoscopic response,
endoscopic remission, and absence of ulceration were
observed in 74 of 83 (89%), 63 of 83 (76%), and 59 of
83 (71%) patients with endoscopic data available at
week 54. An infliximab TC greater than 8.5 mg/L at week
46 and greater than 7.3 mg/L at week 54 were associ-
ated with an absence of ulceration at week 54
(Supplementary Table 3). At all other time points,
infliximab concentrations during maintenance therapy
were not significantly different between patients
achieving the endoscopic outcomes or not (P > .05, data
not shown). However, when pooling all infliximab TCs
from week 14 through week 54, these were significantly
higher in patients achieving absence of ulceration (P <
.0001), with a threshold of 8.9 mg/L established.
The higher infliximab TCs in patients with absence of
ulceration were driven by the subgroup of patients who
earlier were dose-escalated to 10 mg/kg (P < .0001)
(Supplementary Table 3). An infliximab TC greater than
10.6 mg/L on dose escalation was associated with
absence of ulceration at week 54 (PPV, 49%; NPV, 92%;
AUROC, 0.71; 95% CI, 0.62–0.79) (Figure 2C). Although
the median TC at weeks 46 and 54 were similar for pa-
tients on 5 and 10 mg/kg infliximab maintenance doses
(P > .05), the variability in the observed TC was higher in
the latter subgroup (at week 46: IQR, 4.4–8.9 and 3.5–9.8FLA 5.6.0 DTD  YJCGH56531_proof  1on 5 and 10 mg/kg doses, respectively) (Supplementary
Figure 3). Furthermore, the proportion of patients
achieving absence of ulceration were similar on 5-mg/kg
infliximab doses (30 of 37; 81%) and 10-mg/kg inflix-
imab doses (23 of 36; 64%) (P ¼ .121).
Pharmacodynamic monitoring. From week 12 to week
54, fCal was significantly lower in patients achieving the
endoscopic outcomes compared with patients who did
not (Supplementary Figure 2, Supplementary Table 4). At
multiple time points, albumin and CRP also predicted the
endoscopic outcomes both in the univariable and multi-
variable analyses. The lag time between the latest cal-
protectin increase (>250 mg/kg) and the week 54
endoscopic assessment of ulceration was 50 days (IQR,
7–105 d) (wweek 46 infusion) in patients with ulcers
and 111 days (IQR, 53–195 d) (wweek 38 infusion) in
patients without ulcers (P ¼ .009).
Effect of Dose Escalations
A total of 87 dose escalations were performed in 63
patients. Infliximab TCs increased on dose escalation
(from 3.2 mg/L [IQR, 1.2–4.9 mg/L] to 6.0 mg/L [IQR,
3.6–8.9 mg/L] 8 weeks later; P < .0001) (Supplementary
Figure 4A). Eight weeks after dose escalation, infliximab
TCs were similar in patients who achieved the endo-
scopic outcomes and those who did not (also when only















Figure 1. The relationship between infliximab trough con-
centrations during induction therapy and (A) endoscopic
response, (B) endoscopic remission, and (C) absence of ul-
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Figure 2. The distributions of infliximab serum trough concen-
trations at (A) week 2, (B) week 6, and (C) after dose escalation to
10mg/kg in patients achieving mucosal healing (green) and not
(red). (Insert) Receiver operator characteristic curve. The grey
shaded area represents the 95% CI of the specificity (2000
bootstrap replicates).AUROC,areaunder the receiver operating
characteristic curve, FN, false-negative patients; FP, false-
positive patients; LR-, negative likelihood ratio; LRþ, positive
likelihood ratio; NPV, negative predictive value; PPV, positive
predictive value; se, sensitivity; sp, specificity; TN, true-negative










580<3.0 mg/L before dose escalation). Nevertheless, as time
evolved, a separation in infliximab TC became clear be-
tween patients with and without ulceration at week 54
(Figure 3A).
After dose escalation, we observed a significant
decrease in fCal, but not in CRP level (P ¼ .049 and P ¼
.193, respectively) (Supplementary Figure 4B and C). fCal
concentrations measured 8 weeks after dose escalation
were significantly lower in patients who achieved
endoscopic response, endoscopic remission, and absence 16 January 2020  4:57 pm  ce DVC
Figure 3. The relationship
between (A) infliximab
trough concentrations and
(B) fecal calprotectin at
dose escalation and



































































































































695of ulceration at week 54 (P ¼ .010, P ¼ .005, and P ¼
.003, respectively) (Figure 3B and Supplementary
Figure 5). Serum CRP concentrations 8 weeks after
dose escalation were significantly lower in patients
achieving absence of ulceration (5.5 mg/L [IQR, 2.0–8.8
mg/L] vs 1.0 mg/L [IQR, 1.0–3.8 mg/L] for patients
achieving absence of ulceration or not, respectively; P ¼FLA 5.6.0 DTD  YJCGH56531_proof  1.035), but did not differ for the other endoscopic out-
comes. The observed differences in fCal and CRP con-
centrations on dose escalation in terms of outcome
attainment also were observed before dose escalation
(data not shown).
In the subgroup of patients with increased fCal con-
















Figure 4. Fecal calprotectin concentrations at dose escala-
tion between patients achieving (A) endoscopic response, (B)
endoscopic remission, and (C) absence of ulceration at week
54 yes and noQ21 . The red line at 250 mg/kg represents the
normal limit applied in the TAILORIX algorithm.
FLA 5.6.0 DTD  YJCGH56531_proof  1





































































765significant decrease was observed right at dose escala-
tion, resulting in fCal concentrations after dose escalation
that were significantly lower in patients without ulcers
compared with patients with ulcers (P ¼ .033)
(Figure 4). In the subgroup of patients with increased
CRP concentrations before dose escalation (>5.0 mg/L),
a significant decrease was observed only in the patients
who attained the endoscopic outcomes, but the obtained
CRP concentration after dose escalation was not signifi-
cantly different between patients attaining the outcomes






By using a drug-tolerant assay, ATIs were detected in







































In this post hoc analysis of TAILORIX, we identified a
clear relationship between infliximab TCs during induc-
tion therapy and endoscopic outcomes at week 12. We
propose an infliximab TC threshold of 23.1 mg/L at week
2 and of 10.0 mg/L at week 6 based on the PPV of
approximately 70%, indicating that subtherapeutic con-
centrations strongly compromise MH, thereby support-
ing a potential role for early dose optimization toward
these thresholds. The NPV indicates the approximately
60% chance of achieving MH for the patients above the
thresholds as compared with the 51% endoscopic
remission rate in the overall population. Our findings are
consistent with the study by Papamichael et al,13 who
proposed infliximab TC thresholds of 28.3 mg/L and 15.0
mg/L at weeks 2 and 6, respectively, for patients with
ulcerative colitis to attain MH with infliximab induction
therapy. Other studies have identified infliximab TC
thresholds at week 2 (6.8 mg/L,14 16.9 mg/L,15 20.4
mg/L,15 and 21.3 mg/L16) and week 6 (3.5 mg/L14) that
relate to clinical efficacy assessed at week 14. Based on
this comparison with literature data, we conclude that
higher infliximab TCs may need to be targeted for
achieving MH as compared with clinical outcomes.
Nevertheless, prospective studies are warranted to
confirm the causality in the exposure–response rela-
tionship. Although infliximab exposure can alter the
disease activity, variations in disease activity can be
responsible for fluctuations in infliximab exposure as
well.
The clear exposure–response relationship observed
during induction therapy was less convincing during
maintenance therapy. However, in the subgroup of pa-
tients who underwent dose escalation to 10 mg/kg, the




Figure 5. Algorithm imple-










































































































































928week 46. We derived an infliximab TC threshold on dose
escalation of 10.6 mg/L for predicting absence of ulcer-
ation, which is higher than the 3.0 mg/L,17 4.0 mg/L,18
and 6.0 mg/L19 thresholds previously suggested for
achieving MH in patients with CD. As compared with the
5.0 mg/L threshold suggested by Vande Casteele et al8
for symptom control, we conclude that higher inflix-
imab TCs may need to be targeted for achieving MH on
1-year maintenance therapy.
Before dose escalation, the median infliximab TC was
3.2 mg/L. Eight weeks later, the median infliximab TC
was 6.0 mg/L. At weeks 46 and 54, the median infliximab
TC was 6.1 mg/L, with no significant difference between
patients who remained on 5-mg/kg infliximab vs those
who previously were dose-escalated to 10 mg/kg,
showing that overall, the TAILORIX dose escalation al-
gorithm was successful for restoring the infliximab TC.
However, the variability in infliximab TC was larger in
patients who were dose-escalated, showing a clear sep-
aration between endoscopic responders and non-
responders, which eventually allowed the identification
of an exposure–response relationship toward the end of
the maintenance therapy. This observation reinforcesFLA 5.6.0 DTD  YJCGH56531_proof  1that perhaps the lower disease activity in patients with
MH is responsible for the lower infliximab clearance and
thus higher trough concentrations.
Within the subgroup of patients undergoing dose
escalation, the exposure–response relationship was not
observed immediately after dose escalation, but only
after 3 infusions at the increased dose. This may be
explained by the longer time required to reach steady
state in patients with a longer infliximab elimination half-
life (lower clearance). Because the exposure–response
relationship appears only as time evolves, this might
explain why it was observed only toward the end of the
study. Therefore, we conclude that infliximab TCs right
upon dose escalation are not informative for predicting
MH.
By using the prospective TAILORIX cohort, we
validated the use of fCal as a reliable biomarker pre-
dicting endoscopic improvement.20 Already from week
2 onward, fCal concentrations were predictive for MH
and this association persisted throughout the entire
infliximab treatment. Therefore, we recommend moni-
toring of fCal during infliximab therapy. Although
infliximab TC right at dose escalation had no predictive6 January 2020  4:57 pm  ce DVC




















































































































1044value for MH, fCal allowed a rapid distinction between
patients who were likely to achieve absence of ulcer-
ation and those who were not. Therefore, we recom-
mend monitoring of fCal at dose escalation.
Nevertheless, when fCal does not normalize, the
infliximab TC provides information on the mechanism
of failure (PK- vs PD-driven failure) and thus can guide
clinical decision making. Therefore, we recommend a
tiered approach for monitoring infliximab TC (PK
monitoring) and fCal (PD monitoring) during dose
escalation (Figure 5).
Our results support a role for monitoring fCal and TC
during infliximab maintenance therapy. Nevertheless,
TAILORIX did not show improved outcomes when
infliximab doses were escalated based on infliximab TCs
and biomarkers in addition to symptoms. Although
TAILORIX was a pilot study, the primary outcome was
achieved in numerically even more patients in the con-
trol group. However, many patients in the control group
were dose-escalated based on symptoms (irrespective of
fCal and CRP), and response rates were relatively high,
thereby reducing the window of opportunity for addi-
tional TDM. This might be owing to a performance bias
because patients and/or physicians could prompt dose
escalations by over-reporting symptoms, although CDAI
also is known to incur considerable variability in its
scoring.21 Furthermore, as we showed in this post hoc
study, the target of 3.0 mg/L used in TAILORIX was
probably too low for achieving the primary end point
that included absence of ulceration. Besides a well-
chosen control group, a more appropriate target con-
centration, and possibly the opportunity to allow dose
de-escalations, future TDM studies might benefit from 2
recent evolutions in the field of TDM. These evolutions
focus mainly on the application of TDM at the point of
care, using rapid assays and model-based computer-
assisted dosing.22,23 In TAILORIX, dose escalations based
on biomarkers and CDAI were performed at the point of
care (same day as measured), whereas dose escalations
based on infliximab concentrations were not (8 weeks
later), thereby giving unequal chances to PK and PD
monitoring.
This TAILORIX post hoc analysis had some limita-
tions. The analyses were not powered to identify the
predictive value of PK and PD monitoring for targeting
endoscopic outcomes. Although the primary end point of
TAILORIX was corticosteroid-free remission (CDAI,
<150) at all visits between weeks 22 and 54 with the
absence of ulcers at week 54 and no surgery for bowel
resection or abscess, we assessed endoscopic outcomes,
knowing that endoscopic outcomes are associated with
improved clinical outcomes and a reduction of hospital-
izations and surgery.1 In addition, the assessment of
composite end points may impact the ability to identify
relationships when there is heterogeneity between the
different outcome components. Therefore, further anal-
ysis is needed to investigate associations with clinical
outcomes and composite outcomes. In addition, theFLA 5.6.0 DTD  YJCGH56531_proof  1available case analysis may have caused a selection bias
and our findings may not be applicable for other patient
populations (eg, more longstanding CD), patients on
infliximab monotherapy, or patients with prior biological
treatment.
To conclude, the results of this TAILORIX post hoc
analysis support a role for infliximab TC monitoring
during induction therapy. During maintenance therapy,
the identification of an exposure–response relationship
was observed only upon dose escalation. If a patient is
dose-escalated based on increased fCal, the infliximab TC
increases, but it is only a normalization of fCal that
predicts absence of ulceration. Only after a while does
infliximab TC in patients with a persistently increased
fCal (and thus a poor prognosis) tend to be lower than
infliximab TCs in patients with a normalized fCal (and
thus a good prognosis). Nevertheless, to rule out
increased infliximab clearance (eg, resulting from ATIs)
and thus lower exposure, we recommend combining PD
monitoring (based on fCal) with PK monitoring (based
on infliximab TC, and, if necessary, ATI) for reactively
optimizing infliximab maintenance therapy in patients
with CD (Figure 5). Future prospective trials are needed
to evaluate this proposed TDM algorithm in maintenance
therapy.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2019.05.029.6 JanReferences
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Three patterns of ATI detection were observed:
persistent, transient, and on-off switch (Supplementary
Figure 6). ATIs were detected persistently in 9 of 21
patients, despite dose escalation. In 6 of 21 patients, ATIs
were detected following an on-off pattern, masked at
midinfusion samples and after dose escalation. In the
remaining 6 of 21 patients, ATIs were transient, as a
result of or despite dose escalation.Supplementary Figure 1. Proportions of patients with moderat
at week 12 by infliximab concentration quartiles at weeks (A)
attainment  SD, Cochran–Armitage test was used for trend. *
FLA 5.6.0 DTD  YJCGH56531_proof  1Fifteen of 21 (71%) patients with ATIs dropped
out before week 54, mainly because of lack of
improvement (n ¼ 7) and adverse events (n ¼ 3).
Hence, the drop-out rate in ATIþ patients (15 of 21)
was significantly higher compared with patients with
no confirmed ATI positivity (20 of 101 in the full
TAILORIX data set) (P < .0001). Week 54 endoscopies
were performed in 8 of 21 patients with ATIs (of
which 3 were dropouts). All 8 patients achieved
endoscopic remission, 7 achieved endoscopic
response, and 6 had no ulcers at week 54
(Supplementary Table 5).e-to-severe Crohn’s disease achieving endoscopic outcomes
2, (B) 6, (C) 12, and (D) 14. The mean proportion of target
Q24P < .05, **P < .01, ***P < .001.
























































Supplementary Figure 2. The relationship between fecal calprotectin and (A) endoscopic response, (B) endoscopic remission,
and (C) absence of ulceration at weeks 12 and 54 during infliximab induction and maintenance therapy, respectively, in pa-
tients with Crohn’s disease. Tukey box plots, Wilcoxon rank-sum test Q25. *P < .05, **P < .01, ***P < .001, ****P < .0001.
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Supplementary Figure 3. Infliximab trough concentrations at (A) week 46 and (B) week 54 for patients that were on 5, 7.5, and
10 mg/kg infliximab 8 weeks earlier, achieving absence of ulceration at week 54 (in green) or not (in red). Dashed lines indicate
the thresholds established using receiver operating characteristic analysis. Tukey box plots, Wilcoxon rank-sum test.
FLA 5.6.0 DTD  YJCGH56531_proof  16 January 2020  4:57 pm  ce DVC






























































































































Supplementary Figure 4. Tukey box plots representing the change of (A) infliximab trough concentrations, (B) fecal calpro-
tectin concentrations, (C) C-reactive protein in serum, and (D) the Crohn’s disease activity index from before dose escalation
(T0) to 8 weeks later after dose escalation (T1). Green shaded areas and red shaded areas indicate normal and abnormal
values, respectively. A matched-pairs Wilcoxon rank-sum test was used Q26. *P < .05, ***P < .001, ****P < .0001.
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Supplementary Figure 5. Tukey box plots representing the
difference of fecal calprotectin concentrations 8 weeks after
dose escalation between patients achieving (A) endoscopic
response, (B) endoscopic remission, and (C) absence of ul-
ceration at week 54 yes and no. Green shaded areas and red
shaded areas indicate normal and abnormal values, respec-
tively. The Wilcoxon rank-sum test was usedQ27 . **P < .01.
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patterns of antibodies to
infliximab (ATI): (A) persis-
tent, (B) transient, and (C)
on-off switch. Concentra-
tions of infliximab are
shown in green and con-
centrations of ATI are
shown in red. Transparent
vertical lines represent
infliximab infusions of 5
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Supplementary Table 1. The Exposure–Response Relationship During Infliximab Induction Therapy
Time point Endoscopic outcome
Trough Q28concentration,




sp, PPV, NPV, LRþ, LR-)
Week 2 Endoscopic responsea 22.4 [18.7–26.0] (n ¼ 24)b
26.8 [24.9–28.7] (n ¼ 82)c
.068 0.64 (0.50–0.78) 24.2 (0.71, 0.62, 0.35, 0.88, 1.87, 0.47)
Endoscopic remission 23.0 [20.7–25.3] (n ¼ 52)b
28.5 [26.1–30.9] (n ¼ 54)c
.003 0.67 (0.57–0.78) 23.1 (0.56, 0.80, 0.72, 0.65, 2.80, 0.55)
Absence of ulceration 24.1 [22.0–26.1] (n ¼ 64)b
29.3 [26.5–32.0] (n ¼ 38)c
.010 0.64 (0.53–0.75) 25.8 (0.62, 0.61, 0.73, 0.49, 1.59, 0.62)
Week 6 Endoscopic response 13.4 [9.4–17.3] (n ¼ 24)b
19.8 [17.8–21.8] (n ¼ 82)c
.017 0.70 (0.57–0.83) 9.7 (0.54, 0.87, 0.54, 0.87, 4.15, 0.53)
Endoscopic remission 15.8 [13.3–18.4] (n ¼ 52)b
20.7 [18.2–23.2] (n ¼ 54)c
.015 0.64 (0.54–0.75) 10.0 (0.37, 0.89, 0.76, 0.59, 3.36, 0.71)
Absence of ulceration 16.6 [14.3–18.8] (n ¼ 64)b
21.6 [18.6–24.6] (n ¼ 39)c
.020 0.63 (0.52–0.75) 23.5 (0.83, 0.44, 0.71, 0.61, 1.48, 0.39)
Week 12 Endoscopic response 7.0 [4.8–9.2] (n ¼ 23)b
12.5 [11.1–14.0] (n ¼ 82)c
.001 0.77 (0.65–0.88) 8.1 (0.74, 0.76, 0.46, 0.91, 3.08, 0.34)
Endoscopic remission 9.9 [8.0–11.7] (n ¼ 51)b
12.7 [11.0–14.4] (n ¼ 54)c
.045 0.64 (0.53–0.74) 8.1 (0.51, 0.80, 0.70, 0.63, 2.55, 0.61)
Absence of ulceration 10.0 [8.4–11.6] (n ¼ 63)b
13.6 [11.6–15.6] (n ¼ 38)c
.017 0.66 (0.55–0.77) 11.0 (0.73, 0.61, 0.75, 0.57, 1.87, 0.44)
Week 14 Endoscopic response 3.5 [2.1–4.9] (n ¼ 23)b
6.9 [5.9–7.9] (n ¼ 79)c
.002 0.76 (0.64–0.87) 5.2 (0.87, 0.59, 0.38, 0.94, 2.12, 0.22)
Endoscopic remission 5.0 [3.8–6.3] (n ¼ 51)b
7.3 [6.1–8.4] (n ¼ 51)c
.019 0.67 (0.57–0.78) 5.2 (0.67, 0.65, 0.65, 0.66, 1.91, 0.51)
Absence of ulceration 5.3 [4.2–6.3] (n ¼ 61)b
7.7 [6.3–9.1] (n ¼ 37)c
.021 0.67 (0.56–0.78) 4.8 (0.59, 0.70, 0.77, 0.51, 1.97, 0.59)
NOTE. No correction for multiple testing was performed. The Student t test was used for comparing concentrations of patients who did not achieve endoscopic outcomes and for patients who did.
AUROC, area under the receiver operating characteristic curve; LR-, negative likelihood ratio; LRþ, positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; se, sensitivity; sp, specificity.
aStatistical significance was not achieved.
bPatients who did not achieve the endoscopic outcomes.













































































































































































































































































































































































































































































































































Supplementary Table 2.Overview of the Best Models With Predictors for the Endoscopic Outcomes After Infliximab Induction Therapy (at Week 12) in Patients With Crohn’s
Disease










Endoscopic response Endoscopic response Endoscopic response Endoscopic response
Albumin – – – 0.065 0.055 .244 – – – – – –
CRP – – – 0.011 0.085 .896 -0.073 0.056 .188 – – –
fCal – – – -0.0010 0.00053 .050 -0.001 0.00071 .075 -0.003 0.001 .002
Mean platelet volume – – – 0.517 0.396 .192 0.668 0.407 .100 0.744 0.414 .072
Platelet count – – – 0.000011 0.0000047 .016 0.000022 0.0000072 .002 0.000023 0.0000079 .003
Endoscopic remission Endoscopic remission Endoscopic remission Endoscopic remission
Albumin -0.014 0.053 .789 – – – – – – – – –
CRP -0.028 0.013 .029 0.0081 0.040 .840 0.034 0.064 .600 0.028 0.046 .547
fCal – – – -0.0016 0.00051 .001 -0.0038 0.001 .001 -0.002 0.001 .014
Lymphocyte count – – – -0.00063 0.00043 .142 – – – – – –
Mean platelet volume -0.096 0.234 .682 -0.452 0.295 .125 0.557 0.388 .151 – – –
Platelet count – – – – – – 0.000013 0.0000045 .005 0.0000076 0.0000037 .038
White blood cells – – – – – – – – – -0.00021 0.00014 .131
Absence of ulceration Absence of ulceration Absence of ulceration Absence of ulceration
Albumin – – – -0.122 0.084 .149 – – – – – –
CRP – – – 0.076 0.059 .196 – – – – – –
fCal – – – -0.0012 0.00057 .033 – – – – – –
Hematocrit – – – -0.171 0.110 .119 – – – – – –
Mean platelet volume – – – -0.164 0.323 .611 – – – – – –
Platelet count – – – -0.000011 0.0000046 .021 – – – – – –
White blood cells – – – 0.00041 0.00016 .011 – – – – – –
NOTE. Parameter effects can be interpreted only when the z statistic is significant (shown in bold). When a model only contains nonsignificant parameters, no values were provided in the table.
CRP, C-reactive protein; fCal, fecal calprotectin.


















































































































































































































































































































































































































































































































































Supplementary Table 3. The Exposure–Response Relationship During Infliximab Maintenance Therapy
Time point Endoscopic outcome
Trough concentration,
mg/L, means [95% CI] P value
Empiric AUROC,
means (95% CI)
Threshold Youden (se, sp,
PPV, NPV, LRþ, LR-)
Week 46 Absence of ulceration 5.2 [4.6–5.8] (n ¼ 24 Q29)a
7.4 [6.1–8.7] (n ¼ 58)b
.013 0.63 (0.50–0.76) 8.5 (0.88, 0.36, 0.43, 0.88, 1.38, 0.33)
Week 54 Absence of ulceration 5.1 [4.5–5.8] (n ¼ 22)a
8.0 [6.7–9.3] (n ¼ 56)b
.002 0.69 (0.56–0.81) 7.3 (0.86, 0.52, 0.41, 0.91, 1.79, 0.27)
Pooled trough concentrations Absence of ulceration 5.6 [4.8–6.3] (n ¼ 142)a
7.0 [5.7–8.3] (n ¼ 347)b
<.0001 0.58 (0.53–0.63) 8.9 (0.87, 0.28, 0.33, 0.84, 1.21, 0.46)
10 mg/kg subgroup 5.5 [4.6–6.5] (n ¼ 51)a
10.4 [8.9–11.9] (n ¼ 85)b
<.0001 0.71 (0.62–0.79) 10.6 (0.94, 0.42, 0.49, 0.92, 1.62, 0.14)
NOTE. No correction for multiple testing was performed. The Student t test was used for comparing concentrations of patients who did not achieve the endoscopic outcomes and patients who did. Bonferroni correction was
used for multiple testing in the pooled data analysis; a ¼ 0.05/6.
AUROC, area under the receiver operating characteristic curve; LR-, negative likelihood ratio; LRþ, positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; se, sensitivity; sp, specificity.
aPatients who did not achieve the endoscopic outcomes.













































































































































































































































































































































































































































































































































Supplementary Table 4.Overview of the Best Models With Predictors for the Endoscopic Outcomes After Infliximab Maintenance Therapy (at Week 54) in Patients With
Crohn’s Disease


























Albumin – – – 0.348 0.138 .012 0.285 0.173 .100 0.361 0.172 .036 0.265 0.128 .039 – – –
CRP – – – 0.126 0.108 .244 0.106 0.137 .437 0.282 0.252 .263 0.083 0.124 .503 -0.440 0.218 .043
fCal – – – – – – -0.0073 0.0032 .023 – – – – – – -0.0055 0.0028 .046
Hematocrit – – – – – – 0.357 0.197 .071 – – – – – – 0.650 0.398 .103
Hemoglobin – – – 0.874 0.569 .124 – – – – – – – – – – – –
Lymphocyte
count
– – – 0.0014 0.0010 .191 0.0046 0.00222 .039 – – – 0.00122 0.00085 .150 – – –
Platelet count – – – – – – – – – – – – – – – 0.000064 0.000032 .045
Mean platelet
volume













Albumin 0.137 0.0999 .169 – – – – – – 0.101 0.116 .382 -0.016 0.096 .868 – – –
CRP 0.190 0.0969 .050 – – – -0.055 0.045 .218 0.070 0.151 .646 0.021 0.082 .795 -0.050 0.098 .610
fCal -0.0020 0.00095 .037 – – – -0.0025 0.0012 .031 -0.0027 0.0014 .045 -0.0021 0.0010 .027 -0.0033 0.0012 .006
Lymphocyte
count
0.00065 0.00052 .206 – – – – – – – – – 0.00056 0.00048 .245 -0.00074 0.00043 .085
Mean platelet
volume
0.337 0.407 .409 – – – -0.492 0.352 .162 -0.082 0.390 .835 -0.203 0.401 .612 – – –
White blood
cell count













Albumin – – – – – – – – – 0.145 0.135 .281 -0.049 0.111 .657 – – –
CRP – – – – – – -0.115 0.092 .211 -0.200 0.154 .192 -0.130 0.084 .122 -0.584 0.194 .003
fCal – – – – – – -0.0045 0.0017 .008 -0.0030 0.0015 .045 -0.0028 0.0012 .023 -0.0050 0.0019 .008
Hemoglobin – – – – – – – – – 0.467 0.300 .119 – – – – – –
Lymphocyte
count
– – – – – – – – – – – – 0.0024 0.0009 .007 – – –
Platelet count – – – – – – – – – – – – – – – 0.000010 0.0000063 .104
Mean platelet
volume
– – – – – – -0.462 0.371 .214 -0.041 0.454 .929 0.061 0.440 .889 0.521 0.599 .385
White blood
cell count
– – – – – – – – – – – – – – – 0.00101 0.00043 .018
NOTE. Parameter effects can be interpreted only when the z statistic is significant (shown bold). When a model contains only nonsignificant parameters, no values were provided in the table.
CRP, C-reactive protein; fCal, fecal calprotectin.


















































































































































































































































































































































































































































































































































Supplementary Table 5. Endoscopic Outcomes and ATI Patterns of the Eight Patients With ATI With an Available Week 54
Endoscopy
Patient Endoscopic response Endoscopic remission Absence of ulceration ATI pattern
1 Yes Yes Yes On-off switch
2 Yes Yes Yes Persistent
3 Yes Yes Yes Transient
4 No Yes No On-off switch
5 Yes Yes Yes On-off switch
6 Yes Yes Yes On-off switch
7 Yes Yes Yes On-off switch
8 Yes Yes No Transient
ATI, antibodies to infliximab.
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